242 related articles for article (PubMed ID: 22364316)
1. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
[No Abstract] [Full Text] [Related]
2. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail.
Buggiani G; D'Erme AM; Krysenka A; Pescitelli L; Lotti T; Prignano F
Dermatol Ther; 2012; 25(3):283-5. PubMed ID: 22913449
[No Abstract] [Full Text] [Related]
4. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
5. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
Lewis TG; Tuchinda C; Lim HW; Wong HK
J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
[No Abstract] [Full Text] [Related]
7. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Heikkilä H; Ranki A; Cajanus S; Karvonen SL
Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
[No Abstract] [Full Text] [Related]
8. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
[No Abstract] [Full Text] [Related]
9. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
Lisby S; Gniadecki R
Acta Derm Venereol; 2004; 84(3):247-8. PubMed ID: 15202853
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
11. Erythrodermic psoriasis and secukinumab: Our clinical experience.
Mateu-Puchades A; Santos-Alarcón S; Martorell-Calatayud A; Pujol-Marco C; Sánchez-Carazo JL
Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
[No Abstract] [Full Text] [Related]
12. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
Rongioletti F; Borenstein M; Kirsner R; Kerdel F
J Dermatolog Treat; 2003 Dec; 14(4):222-5. PubMed ID: 14660268
[TBL] [Abstract][Full Text] [Related]
13. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
Takahashi MD; Castro LG; Romiti R
Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
[No Abstract] [Full Text] [Related]
14. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
Downs AM
Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
[No Abstract] [Full Text] [Related]
15. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
Dogra S; Bishnoi A; Narang T; Handa S
Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
[No Abstract] [Full Text] [Related]
16. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of treatment strategies for erythrodermic psoriasis.
Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
J Dermatolog Treat; 2021 Feb; 32(1):49-55. PubMed ID: 31682547
[No Abstract] [Full Text] [Related]
18. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Rallis E; Verros CD
Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
[No Abstract] [Full Text] [Related]
19. Erythroderma in the era of biological therapies.
Zattra E; Belloni Fortina A; Peserico A; Alaibac M
Eur J Dermatol; 2012; 22(2):167-71. PubMed ID: 22321651
[TBL] [Abstract][Full Text] [Related]
20. Erythrodermic psoriasis.
Mumoli N; Vitale J; Gambaccini L; Sabatini S; Brondi B; Cei M
QJM; 2014 Apr; 107(4):315. PubMed ID: 23764512
[No Abstract] [Full Text] [Related]
[Next] [New Search]
